Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.
Merck (MRK) stock is in focus as the company's Keytruda versions win FDA priority review for an expanded indication in ...
FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback